Louis J Lombardo

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8777362/publications.pdf

Version: 2024-02-01

49 papers	4,124 citations	201575 27 h-index	197736 49 g-index
49 all docs	49 docs citations	49 times ranked	5089 citing authors

#	Article	IF	Citations
1	Discovery of BMS-986202: A Clinical Tyk2 Inhibitor that Binds to Tyk2 JH2. Journal of Medicinal Chemistry, 2021, 64, 677-694.	2.9	41
2	Long-Acting Tumor-Activated Prodrug of a TGFÎ²R Inhibitor. Journal of Medicinal Chemistry, 2021, 64, 15787-15798.	2.9	2
3	Identification of N-Methyl Nicotinamide and N-Methyl Pyridazine-3-Carboxamide Pseudokinase Domain Ligands as Highly Selective Allosteric Inhibitors of Tyrosine Kinase 2 (TYK2). Journal of Medicinal Chemistry, 2019, 62, 8953-8972.	2.9	59
4	Highly Selective Inhibition of Tyrosine Kinase 2 (TYK2) for the Treatment of Autoimmune Diseases: Discovery of the Allosteric Inhibitor BMS-986165. Journal of Medicinal Chemistry, 2019, 62, 8973-8995.	2.9	212
5	Identification of Imidazo[1,2-b]pyridazine Derivatives as Potent, Selective, and Orally Active Tyk2 JH2 Inhibitors. ACS Medicinal Chemistry Letters, 2019, 10, 383-388.	1.3	40
6	Identification of potent tricyclic prodrug S1P1 receptor modulators. MedChemComm, 2017, 8, 725-729.	3.5	6
7	Structure-Based Design of Selective Janus Kinase 2 Imidazo[4,5-d]pyrrolo[2,3-b]pyridine Inhibitors. ACS Medicinal Chemistry Letters, 2015, 6, 845-849.	1.3	11
8	Discovery of a Highly Selective JAK2 Inhibitor, BMS-911543, for the Treatment of Myeloproliferative Neoplasms. ACS Medicinal Chemistry Letters, 2015, 6, 850-855.	1.3	35
9	Discovery of Clinical Candidate BMS-906024: A Potent Pan-Notch Inhibitor for the Treatment of Leukemia and Solid Tumors. ACS Medicinal Chemistry Letters, 2015, 6, 523-527.	1.3	79
10	9H-Carbazole-1-carboxamides as potent and selective JAK2 inhibitors. Bioorganic and Medicinal Chemistry Letters, 2015, 25, 2809-2812.	1.0	8
11	Benzazepinones and Benzoxazepinones as Antagonists of Inhibitor of Apoptosis Proteins (IAPs) Selective for the Second Baculovirus IAP Repeat (BIR2) Domain. Journal of Medicinal Chemistry, 2013, 56, 7772-7787.	2.9	26
12	Optimization of Benzodiazepinones as Selective Inhibitors of the X-Linked Inhibitor of Apoptosis Protein (XIAP) Second Baculovirus IAP Repeat (BIR2) Domain. Journal of Medicinal Chemistry, 2013, 56, 7788-7803.	2.9	31
13	Identification of a phenylacylsulfonamide series of dual Bcl-2/Bcl-xL antagonists. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 3946-3950.	1.0	30
14	Pyrazole and pyrimidine phenylacylsulfonamides as dual Bcl-2/Bcl-xL antagonists. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 3951-3956.	1.0	22
15	Pyrrolo[1,2-f]triazines as JAK2 inhibitors: Achieving potency and selectivity for JAK2 over JAK3. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 1425-1428.	1.0	17
16	Design, synthesis and structureâ€“activity relationships of novel biarylamine-based Met kinase inhibitors. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 2998-3002.	1.0	16
17	The Antiangiogenic Activity in Xenograft Models of Brivanib, a Dual Inhibitor of Vascular Endothelial Growth Factor Receptor-2 and Fibroblast Growth Factor Receptor-1 Kinases. Molecular Cancer Therapeutics, 2010, 9, 369-378.	1.9	72
18	Characterization of BMS-911543, a Functionally Selective Small Molecule Inhibitor of JAK2. Blood, 2010, 116, 4112-4112.	0.6	3

#	Article	IF	Citations
19	Assessing compound binding to the Eg5 motor domain using a thermal shift assay. Analytical Biochemistry, 2009, 392, 59-69.	1.1	19
20	Discovery of N-(4-(2-Amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide (BMS-777607), a Selective and Orally Efficacious Inhibitor of the Met Kinase Superfamily. Journal of Medicinal Chemistry, 2009, 52, 1251-1254.	2.9	265
21	One-pot two step synthesis of 5-cyano-dihydropyrimidinones using polyphosphate ester. Tetrahedron Letters, 2008, 49, 3009-3010.	0.7	18
22	Synthesis, SAR, and Evaluation of 4-[2,4-Difluoro-5-(cyclopropylcarbamoyl)phenylamino]pyrrolo[2,1-f][1,2,4]triazine-based VEGFR-2 kinase inhibitors. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 1354-1358.	1.0	27
23	Identification of pyrrolo[2,1-f][1,2,4]triazine-based inhibitors of Met kinase. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 1945-1951.	1.0	56
24	Discovery and preclinical studies of 5-isopropyl-6-(5-methyl-1,3,4-oxadiazol-2-yl)-N-(2-methyl-1H-pyrrolo[2,3-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine (BMS-645737), an in vivo active potent VEGFR-2 inhibitor. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 2985-2989.	1.0	18
25	Discovery of orally active pyrrolopyridine- and aminopyridine-based Met kinase inhibitors. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 3224-3229.	1.0	62
26	Discovery of Pyrrolopyridineâ"Pyridone Based Inhibitors of Met Kinase: Synthesis, X-ray Crystallographic Analysis, and Biological Activities. Journal of Medicinal Chemistry, 2008, 51, 5330-5341.	2.9	115
27	Discovery of Brivanib Alaninate ((S)-((R)-1-(4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan-2-yl 2- A Novel Prodrug of Dual Vascular Endothelial Growth Factor Receptor-2 and Fibroblast Growth Factor Receptor-1 Kinase Inhibitor (BMS-540215). Journal of Medicinal Chemistry, 2008, 51, 1976-1980.	2.9	135
28	Metabolism of 5-Isopropyl-6-(5-methyl-1,3,4-oxadiazol-2-yl)-N-(2-methyl-1H-pyrrolo[2,3-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]tr (BMS-645737): Identification of an UnusualN-Acetylglucosamine Conjugate in the Cynomolgus Monkey. Drug Metabolism and Disposition, 2008, 36, 2475-2483.	1.7	6
29	Efficacy, Pharmacokinetics, and Metabolism of Tetrahydroquinoline Inhibitors of Plasmodium falciparum Protein Farnesyltransferase. Antimicrobial Agents and Chemotherapy, 2007, 51, 3659-3671.	1.4	40
30	Second Generation Tetrahydroquinoline-Based Protein Farnesyltransferase Inhibitors as Antimalarials. Journal of Medicinal Chemistry, 2007, 50, 4585-4605.	2.9	66
31	In Vitro Cardiotoxicity Potential Comparative Assessments of Chronic Myelogenous Leukemia Tyrosine Kinase Inhibitor Therapies: Dasatinib, Imatinib and Nilotinib.. Blood, 2007, 110, 4582-4582.	0.6	19
32	Discovery and Preclinical Studies of (R)-1-(4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 227 Td (methy Inhibitor. Journal of Medicinal Chemistry, 2006, 49, 2143-2146.	2.9	136
33	Discovery and Evaluation ofN-Cyclopropyl- 2,4-difluoro-5-((2-(pyridin-2-ylamino)thiazol-5-) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50 Endothelial Growth Factor Receptor-2. Journal of Medicinal Chemistry, 2006, 49, 3766-3769.	2.9	40
34	Inhibitors of human mitotic kinesin Eg5: Characterization of the 4-phenyl-tetrahydroisoquinoline lead series. Bioorganic and Medicinal Chemistry Letters, 2006, 16, 2095-2100.	1.0	46
35	Synthesis and SAR of pyrrolotriazine-4-one based Eg5 inhibitors. Bioorganic and Medicinal Chemistry Letters, 2006, 16, 3937-3942.	1.0	49
36	The Structure of Dasatinib (BMS-354825) Bound to Activated ABL Kinase Domain Elucidates Its Inhibitory Activity against Imatinib-Resistant ABL Mutants. Cancer Research, 2006, 66, 5790-5797.	0.4	610

#	Article	IF	Citations
37	Design, synthesis, and structureâ€“activity relationships of tetrahydroquinoline-based farnesyltransferase inhibitors. Bioorganic and Medicinal Chemistry Letters, 2005, 15, 1895-1899.	1.0	21
38	Protein Farnesyltransferase Inhibitors Exhibit Potent Antimalarial Activity. Journal of Medicinal Chemistry, 2005, 48, 3704-3713.	2.9	170
39	Design, Synthesis, and Evaluation of Orally Active 4-(2,4-Difluoro-5-(methoxycarbamoyl)phenylamino)pyrrolo[2,1-f][1,2,4]triazines as Dual Vascular Endothelial Growth Factor Receptor-2 and Fibroblast Growth Factor Receptor-1 Inhibitors. Journal of Medicinal Chemistry, 2005, 48, 3991-4008.	2.9	65
40	Dasatinib (BMS-354825) Overcomes Multiple Mechanisms of Imatinib Resistance in Chronic Myeloid Leukemia (CML).. Blood, 2005, 106, 1994-1994.	0.6	10
41	The Identification and Optimization of Orally Efficacious, Small Molecule VLA-4 Antagonists. Current Topics in Medicinal Chemistry, 2004, 4, 1473-1484.	1.0	31
42	Apoptotic and Cytostatic Farnesyltransferase Inhibitors Have Distinct Pharmacology and Efficacy Profiles in Tumor Models. Cancer Research, 2004, 64, 3974-3980.	0.4	20
43	Discovery ofN-(2-Chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4-) Tj ETQq1 1 0.784314 rgBT /O Activity in Preclinical Assays. Journal of Medicinal Chemistry, 2004, 47, 6658-6661.	2.9	1,196
44	Pharmacokinetics- and Pharmacodynamics-Guided Optimization of the Dose and Treatment Schedule for the Dual SRC/ABL Inhibitor BMS-354825.. Blood, 2004, 104, 1987-1987.	0.6	2
45	BMS-354825, a Dual SRC/ABL Kinase Inhibitor, Displays Potent Anti-Tumor Activity in a Model of Intracranial CML Growth.. Blood, 2004, 104, 1988-1988.	0.6	5
46	The Crystal Structure of Abl Kinase with BMS-354825, a Dual SRC/ABL Kinase Inhibitor.. Blood, 2004, 104, 553-553.	0.6	21
47	Antihyperglycemic activity of novel naphthalenylmethyl-3H-1,2,3,5-oxathiadiazole 2-oxides. Journal of Medicinal Chemistry, 1993, 36, 2485-2493.	2.9	20
48	The chemistry of vicinal tricarbonyls a total synthesis of prodigiosin. Tetrahedron Letters, 1989, 30, 1725-1728.	0.7	61
49	The chemistry of vicinal tricarbonyls. A stable vinyl tricarbonyl hydrate as a di- and trielectrophile. Journal of the American Chemical Society, 1989, 111, 371-372.	6.6	65